Synthetic Biology for Engineering Applications (R01) | Interagency Modeling and Analysis Group.
PAR-16-116: Bioengineering Research Partnerships (U01) Department of Health and Human Services Part 1. Overview Information Participating Organization(s) National Institutes of Health (NIH) Components of Participating Organizations National Institute of Biomedical Imaging and Bioengineering (NIBIB) National Cancer Institute (NCI) National Eye Institute (NEI) National Institute on Alcohol Abuse and Alcoholism (NIAAA) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institute on Drug Abuse (NIDA) National Institute of Environmental Health Sciences (NIEHS) National Institute of Neurological Disorders and Stroke (NINDS) Funding Opportunity Title Bioengineering Research Partnerships (U01) Activity Code U01 Research Project – Cooperative Agreements Related Notices May 10, 2017 - New NIH "FORMS-E" Grant Application Forms and Instructions Coming for Due Dates On or After January 25, 2018.
Funding Opportunity Announcement (FOA) Number Companion Funding Opportunity Funding Opportunity Purpose Key Dates Part 1. 1. 2. Untitled. Department of Health and Human Services Part 1. Overview Information Participating Organization(s) National Institutes of Health (NIH) Components of Participating Organizations Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Funding Opportunity Title NIH Exploratory/Developmental Research Grant Program ( Parent R21) Activity Code R21 Exploratory/Developmental Research Grant May 10, 2017 - New NIH "FORMS-E" Grant Application Forms and Instructions Coming for Due Dates On or After January 25, 2018. Funding Opportunity Announcement (FOA) Number Companion Funding Opportunity Catalog of Federal Domestic Assistance (CFDA) Number(s) Funding Opportunity Purpose The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects.
Key Dates Open Date (Earliest Submission Date) Letter of Intent Due Date(s) Application Due Date(s) AIDS Application Due Date(s) Table of Contents. Untitled. Sample Applications & More | NIH: National Institute of Allergy and Infectious Diseases. AHA Institutional Research Enhancement Award (AIREA) Class com.aha.ucm.component.cis.TagListPageData=[,docNativeURL=null,docName=UCM_489540,docStatus=RELEASED,dOutDate=null,docSSFileName=UCM_489540_AHA-Institutional-Research-Enhancement-Award-AIREA.jsp,docTitle=AHA Institutional Research Enhancement Award (AIREA),xWebsites=professional,dDocAuthor=stacy.ragsdale,xNextReviewDate=01/27/2016 8:46 PM,xTier1=35,xFeaturedItem=No,xElectronicRegistration=No,UserLocale=null,xSubCategory=,dpEvent=null,xComments=Program description, eligibility and peer review criteria for the AHA's AHA Institutional Research Enhancement Award (AIREA.
Agreements - FAPESP and the National Institutes of Health (NIH) Collaborative Research Opportunity. This call is published at www.fapesp.br/10025 1. Introduction The National Institutes of Health (NIH) USA and the São Paulo Research Foundation (FAPESP), Brazil have signed a MoU to encourage collaborative international research between investigators in the USA and in the State of São Paulo, Brazil.
Under the referred MoU, as an action to promote such collaboration, FAPESP announces this Call for Proposals inviting researchers associated to Higher Education and Research Organizations in the State of São Paulo to submit research proposals. This Call for Proposals is issued in coordination with the Notice of Information from the NIH: Parallel Funding Initiative for Collaborative Research Between Investigators in the USA and in the State of São Paulo, Brazil ( Applications must be collaborations between researchers in the USA and in the State of São Paulo, Brazil. 2. 2.1. 2.2. 2.3. 2.4. 3. 3.1 Eligibility criteria 4. 5.
NOT-TW-16-001: Notice of Information: Parallel Funding Initiative for Collaborative Research Between Investigators in the USA and in the State of So Paulo, Brazil. Notice of Information: Parallel Funding Initiative for Collaborative Research Between Investigators in the USA and in the State of São Paulo, Brazil Notice Number: NOT-TW-16-001 Key DatesRelease Date: January 12, 2016 Related AnnouncementsPA-16-160PA-13-302 Purpose The National Institute of Health (NIH) and the São Paulo Research Foundation (FAPESP), Brazil, have signed a memorandum of understanding (MOU) to encourage collaborative international research between investigators in the US and in the State of São Paulo. The two funding agencies intend to jointly support (parallel funding) successful R01 applications to the NIH that fall within research areas of mutual interest, including single disciplinary and cross-disciplinary approaches and topics.
Instructions to Applicants 1. 2. 3. 4. 5. 6. Inquiries General inquiries about this initiative should be directed to: Kevin Bialy, MAA Fogarty International Center (FIC) Telephone: 301-496-6273 Email: Kevin.Bialy@nih.gov Margaret M. Margarita R. Page Limits | grants.nih.gov. Tissue Engineering and Regenerative Medicine | National Institute of Biomedical Imaging and Bioengineering. Cells are the building blocks of tissue, and tissues are the basic unit of function in the body. Generally, groups of cells make and secrete their own support structures, called extra-cellular matrix. This matrix, or scaffold, does more than just support the cells; it also acts as a relay station for various signaling molecules. Thus, cells receive messages from many sources that become available from the local environment. Each signal can start a chain of responses that determine what happens to the cell. By understanding how individual cells respond to signals, interact with their environment, and organize into tissues and organisms, researchers have been able to manipulate these processes to mend damaged tissues or even create new ones.
The process often begins with building a scaffold from a wide set of possible sources, from proteins to plastics. Another method to create new tissue uses an existing scaffold. NOT-OD-16-134: Revised: Projected FY 2017 Stipend Levels for Postdoctoral Trainees and Fellows on Ruth L. Kirschstein National Research Service Awards (NRSA) Revised: Projected FY 2017 Stipend Levels for Postdoctoral Trainees and Fellows on Ruth L. Kirschstein National Research Service Awards (NRSA) Notice Number: NOT-OD-16-134 Key DatesRelease Date: August 10, 2016 Related AnnouncementsNOT-OD-17-002NOT-OD-16-131 - RescindedNOT-OD-16-062 Issued by National Institutes of Health (NIH) Agency for Healthcare Research and Quality (AHRQ) Health Resources Services Administration (HRSA) Purpose This Notice revises NOT-OD-16-131 to correct an error in the effective date.
These projected new stipend levels are planned to be effective December 1, 2016. The exact stipend levels and the actual date of implementation are subject to the availability of FY 2017 appropriations and implementation of the new FLSA threshold for professional workers to be eligible for paid overtime. Projected Postdoctoral Stipend levels for FY2017 Background The new FLSA paid overtime rule sets a salary level of $47,476 for professional employees to be exempt from paid overtime.
Individual Fellowships | Research Training and Career Development. Skip Navigation U.S. Department of Health & Human Services National Institutes of Health Division of Biomedical Research Workforce Contact Us Individual Fellowships RTCD Home > Program Details Ruth L. Program Purpose The purpose of the Kirschstein-NRSA senior individual fellowships is to enable experienced scientists to make major changes in the direction of their research careers or to broaden their scientific background by acquiring new research capabilities as independent investigators.
Eligibility Career level U.S. citizen or permanent resident, with at least 7 years of Post-Doctoral degree research experience. Established Investigator U.S. domestic institutions, Foreign Institutions. Relevant Policy Notices Forms and other Guidelines Currently Supported Investigators Search for currently supported investigators using NIH RePORTER Program Data, Outcomes and Evaluations Download Reader: Readers for Documents on the Page Adobe Acrobat Reader Download NIH Funding Opportunity Announcements Ruth L. Glycosaminoglycan. Glycosaminoglycans[1] (GAGs) or mucopolysaccharides[2] are long unbranched polysaccharides consisting of a repeating disaccharide unit. The repeating unit (except for keratan) consists of an amino sugar (N-acetylglucosamine or N-acetylgalactosamine) along with a uronic sugar (glucuronic acid or iduronic acid) or galactose.[3] Glycosaminoglycans are highly polar and attract water.
They are therefore useful to the body as a lubricant or as a shock absorber. Mucopolysaccharidoses are a group of metabolic disorders in which abnormal accumulations of glycosaminoglycans occur because of enzyme deficiencies. Production[edit] Glycosaminoglycans have high degrees of heterogeneity with regards to molecular mass, disaccharide construction, and sulfation due to the fact that GAG synthesis, unlike proteins or nucleic acids, is not template driven, and dynamically modulated by processing enzymes.[4] Function[edit] Endogenous heparin is localized and stored in secretory granules of mast cells.
Additive Manufacturing | Laser Zentrum Hannover e.V. Laser Development Department | Laser Zentrum Hannover e.V. The Laser Development Department concentrates on the development of laser sources for a variety of applications. The research focus areas of the LZH in the field of laser development are in designing and characterizing modern, diode-pumped solid-state and fiber lasers. In the framework of their activities, the Laser Development Department covers the complete spectrum, from basic research to industrial applications.
In the field of ultrashort pulse fiber oscillators, resonator-internal pulse dynamics for energy scaling are being investigated. Innovative concepts for compact, mode-locked fiber oscillators with wavelengths around 2 µm are being developed for structuring organic solar cells. Further scaling of the pulse energy for the wavelength of 2 µm using regenerative amplifiers are also being developed. Another focus of research of the department is the realization of highly-stable, single-frequency, diode-pumped solid-state lasers and laser amplifiers for gravitational wave detection. Biofabrication Group | Laser Zentrum Hannover e.V. Biofabrication Group Work of the group focuses on: Laser-based generation of structures (scaffolds) from biocompatible materials for tissue engineering using two-photon-polymerization Replication of these structures from biological materials via molding “Printing” of living cells in specific patterns for investigations on cell-cell and cell-environment interaction Three-dimensional cell “printing” to generate biological tissue Current scientific work and projects:
Fastlane.nsf. SBIR / STTR Gateway - News and Search Engine. Site:sbir.gov tissue engineering. Open Topic Search | SBIR.gov. Open Topic Search | SBIR.gov. Pancreatic cancer (adenocarcinoma pancreatis) 200x. CDRH Learn. Premarket Notification (510k) The 510(k) ProgramPresentation Printable Slides Transcript Premarket Notification 510(k) OverviewPresentation Printable Slides 510(k) Format Guidance, Including Standards Form, and Extensions/Clinical Trial Form and 510(k)Presentation Printable Slides 510(k) Third Party ReviewPresentation Printable Slides 510(k) Electronic Submission Pilot ProgramPrintable Slides Transcript De Novo De Novo ProgramPresentation Printable Slides Transcript Clinical Studies/Investigational Device Exemption (IDE) IDE BasicsPresentation Printable Slides Transcript Early Feasibility Study (EFS) ProgramPresentation Strengthening the Medical Device Clinical Trial EnterprisePresentation Printable Slides Transcript IDEs for Early Feasibility Medical Device Clinical Studies, Including First in Human (FIH) StudiesPresentation Printable Slides Transcript FDA Guidance: Design Considerations for Pivotal Clinical Investigations for Medical DevicesPresentation Printable Slides Transcript Pre-Submissions.
Search Results: bioreactor medical device. Showing 1 - 10 of about 71 for bioreactor medical device July 2015 PMA Approvals Medical Devices 2015-10-23 | www.fda.gov/... /productsandmedicalprocedures/deviceapprovalsandclearances/pmaapprovals/ucm461320.htm ... TN 38132, Approval for increasing the bioreactor used to ... The device, as modified, will be marketed under ... Cached PDF Regulatory Science Progress Report FY 2013 - FY 2014 Regulatory Information www.fda.gov/... ... established, including the Medical Device Innovation Consortium, ... of approved medical countermeasure. ...
Text Version PDF Class of 2009 Overview.pub About FDA 2015-04-14 | www.fda.gov/... ... pro‐ ject will explore how medical device design features ... consequences in the veterinary medical field as it ... and a perfusion flow bioreactor, on the ... Text Version PDF The critical path initiative Science & Research 2010-08-06 | www.fda.gov/downloads/scienceresearch/specialtopics/criticalpathinitiative/ucm221651.pdf Text Version ...
Text Version ... Cached Text Version ... RFA-HL-15-008: Bioreactors for Reparative Medicine (R43/R44) Department of Health and Human Services Part 1. Overview Information Participating Organization(s) National Institutes of Health (NIH) Components of Participating Organizations National Heart, Lung, and Blood Institute (NHLBI) National Institute of Biomedical Imaging and Bioengineering (NIBIB) National Center for Advancing Translational Sciences (NCATS) Funding Opportunity Title Bioreactors for Reparative Medicine (R43/R44) Activity Code R43/R44 Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, and Fast-Track Related Notices NOT-OD-16-004 - NIH & AHRQ Announce Upcoming Changes to Policies, Instructions and Forms for 2016 Grant Applications (November 18, 2015) NOT-OD-16-006 - Simplification of the Vertebrate Animals Section of NIH Grant Applications and Contract Proposals (November 18, 2015) NOT-OD-16-011 - Implementing Rigor and Transparency in NIH & AHRQ Research Grant Applications (November 18, 2015) Funding Opportunity Announcement (FOA) Number Companion Funding Opportunity.
RFA-HL-15-008: Bioreactors for Reparative Medicine (R43/R44) Cholestatic Jaundice. Pathway Home Population Covered By The Guidance This pathway provides a diagnostic imaging algorithm for patients with clinically and biochemically suspected cholestatic jaundice. Date reviewed: April 2015 Date of next review: April 2017 Published: July 2015 Quick User Guide Move the mouse cursor over the PINK text boxes inside the flow chart to bring up a pop up box with salient points.Clicking on the PINK text box will bring up the full text.The relative radiation level (RRL) of each imaging investigation is displayed in the pop up box. Pathway Pathway Diagram Teaching Points Teaching Points Ultrasound is the first imaging modality used in the algorithm for the investigation of cholestatic jaundice Further imaging depends on whether the bile ducts are dilated If the bile ducts are dilated and an ultrasound fails to demonstrate a cause, further imaging depends on a provisional clinical diagnosis.
Chol_jau Cholestatic Jaundice Computed Tomography (CT) ctc ercp Endoscopic Ultrasonography (EUS) hep_jaun.